Claims for Patent: 8,889,834

Summary for Patent: 8,889,834

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	14/260,985
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,889,834
Patent Claims:	1. An isolated monoclonal antibody that binds to an epitope of PCSK9 that comprises at least three of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 2. The isolated monoclonal antibody of claim 1, wherein the isolated antibody is a human antibody. 3. The isolated monoclonal antibody of claim 2, wherein the isolated antibody comprises a light chain that comprises the amino acid sequence of SEQ ID NO: 157. 4. The isolated monoclonal antibody of claim 2, wherein the isolated antibody is a neutralizing antibody. 5. The isolated monoclonal antibody of claim 4, further comprising a light chain that comprises the amino acid sequence of SEQ ID NO: 157. 6. The isolated monoclonal antibody of claim 5, wherein the isolated antibody binds to human PCSK9 with a K.sub.D of less than or equal to 5.times.10.sup.-9 M. 7. The isolated monoclonal antibody of claim 6, wherein the K.sub.D is measured at a pH of less than 7.4. 8. The isolated monoclonal antibody of claim 5, wherein the epitope comprises at least four of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1. 9. The isolated monoclonal antibody of claim 5, wherein the epitope is a functional epitope. 10. The isolated monoclonal antibody of claim 5, wherein the epitope is a structural epitope. 11. An isolated monoclonal antibody specific for binding PCSK9 that binds to at least three of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 12. The isolated monoclonal antibody of claim 11, wherein the isolated antibody is a human antibody. 13. The isolated monoclonal antibody of claim 12, wherein the isolated antibody comprises a light chain that comprises the amino acid sequence of SEQ ID NO: 157. 14. The isolated monoclonal antibody of claim 11, wherein the isolated antibody is a neutralizing antibody. 15. The isolated monoclonal antibody of claim 14, wherein the isolated antibody binds to human PCSK9 with a K.sub.D of less than or equal to 5.times.10.sup.-9 M. 16. The isolated monoclonal antibody of claim 15, wherein the KD is measured at a pH of less than 7.4. 17. The isolated monoclonal antibody of claim 14, wherein the isolated antibody competes for binding to PCSK9 with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 49 and a light chain variable region having an amino acid sequence of SEQ ID NO: 23. 18. The isolated monoclonal antibody of claim 11, wherein the isolated antibody competes for binding to PCSK9 with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 49 and a light chain variable region having an amino acid sequence of SEQ ID NO: 23. 19. An isolated monoclonal antibody specific for binding PCSK9 that binds to at least four of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 20. An isolated human monoclonal neutralizing antibody that binds to an epitope of PCSK9 containing at least one of amino acids 162, 164, 167, 207 or 208 of SEQ ID NO: 1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.

Details for Patent 8,889,834

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	08/27/2015		2027-08-23
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	07/08/2016		2027-08-23

International Patent Family for US Patent 8,889,834

Country	Patent Number	Estimated Expiration
Argentina	068011
Argentina	110799
Australia	2008288791
Australia	2013203677
Australia	2013203685
Australia	2013203689